Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation

NCT02196961 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Merkel Cell Carcinoma

Interventions

DRUG: Nivolumab

Sponsor

Prof. Dr. med. Dirk Schadendorf

Collaborators

[object Object]